259 related articles for article (PubMed ID: 34997443)
1. Neonatal Fc Receptor-Targeted Therapies in Neurology.
Nelke C; Spatola M; Schroeter CB; Wiendl H; Lünemann JD
Neurotherapeutics; 2022 Apr; 19(3):729-740. PubMed ID: 34997443
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.
Gable KL; Guptill JT
Front Immunol; 2019; 10():3052. PubMed ID: 31998320
[TBL] [Abstract][Full Text] [Related]
3. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.
Wolfe GI; Ward ES; de Haard H; Ulrichts P; Mozaffar T; Pasnoor M; Vidarsson G
J Neurol Sci; 2021 Nov; 430():118074. PubMed ID: 34563918
[TBL] [Abstract][Full Text] [Related]
4. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
5. FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N; Karmastaji S; Matic A; Bril V
CNS Drugs; 2024 Jun; 38(6):425-441. PubMed ID: 38724842
[TBL] [Abstract][Full Text] [Related]
6. Fc-Receptor Targeted Therapies for the Treatment of
Keller CW; Pawlitzki M; Wiendl H; Lünemann JD
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155
[No Abstract] [Full Text] [Related]
7. Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody.
Kenniston JA; Taylor BM; Conley GP; Cosic J; Kopacz KJ; Lindberg AP; Comeau SR; Atkins K; Bullen J; TenHoor C; Adelman BA; Sexton DJ; Edwards TE; Nixon AE
J Biol Chem; 2017 Oct; 292(42):17449-17460. PubMed ID: 28878017
[TBL] [Abstract][Full Text] [Related]
8. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.
Peter HH; Ochs HD; Cunningham-Rundles C; Vinh DC; Kiessling P; Greve B; Jolles S
J Allergy Clin Immunol; 2020 Sep; 146(3):479-491.e5. PubMed ID: 32896308
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.
Liu L; Garcia AM; Santoro H; Zhang Y; McDonnell K; Dumont J; Bitonti A
J Immunol; 2007 Apr; 178(8):5390-8. PubMed ID: 17404325
[TBL] [Abstract][Full Text] [Related]
10. [Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].
Murai H; Harada D
Brain Nerve; 2024 Feb; 76(2):183-191. PubMed ID: 38351566
[TBL] [Abstract][Full Text] [Related]
11. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
[TBL] [Abstract][Full Text] [Related]
12. Research progress on neonatal Fc receptor and its application.
Hu M; Wei S; Zhou W; Wang P
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):537-544. PubMed ID: 34704415
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
14. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
15. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
Sun Y; Estevez A; Schlothauer T; Wecksler AT
MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
[TBL] [Abstract][Full Text] [Related]
16. Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias.
Wyckoff SL; Hudson KE
Transfusion; 2021 May; 61(5):1350-1354. PubMed ID: 33650699
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease.
Mina-Osorio P; Tran MH; Habib AA
Transfus Med Rev; 2024 Jan; 38(1):150767. PubMed ID: 37867088
[TBL] [Abstract][Full Text] [Related]
18. Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune Encephalomyelitis.
Remlinger J; Madarasz A; Guse K; Hoepner R; Bagnoud M; Meli I; Feil M; Abegg M; Linington C; Shock A; Boroojerdi B; Kiessling P; Smith B; Enzmann V; Chan A; Salmen A
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35027475
[TBL] [Abstract][Full Text] [Related]
19. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
20. FcRN receptor antagonists in the management of myasthenia gravis.
Bhandari V; Bril V
Front Neurol; 2023; 14():1229112. PubMed ID: 37602255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]